The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Clinical Uses of Intravenous Immunoglobulins

Samuel A. Berkman, MD; Martin L. Lee, PhD; and Robert Peter Gale, MD, PhD
[+] Article, Author, and Disclosure Information

Requests for Reprints: Samuel Berkman, MD, 435 N. Bedford Drive, No. 308, Beverly Hills, CA 90210.

Current Author Addresses: Dr. Berkman: 435 N. Bedford Drive, No. 308, Beverly Hills, CA 90210.

Dr. Lee: Hyland Division, Baxter Healthcare Corp., Glendale, CA 91203.

Dr. Gale: Department of Medicine, Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA 90024.

©1990 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1990;112(4):278-292. doi:10.7326/0003-4819-112-4-278
Text Size: A A A

Purpose: To ascertain the activity of intravenous immunoglobulin in a wide range of diseases.

Data Identification: English-language literature search using MEDLINE (1982 to 89), review of meeting reports, and extensive hand searching of bibliographies of identified articles.

Study Selection: All identified articles.

Data Extraction: Study quality and specific descriptive information concerning population, intervention, and outcome measurements were assessed.

Results of Data Synthesis: There have been few controlled, randomized trials of intravenous immunoglobulin. Available data suggest efficacy in persons with primary immune deficiency, premature infants at risk for group B streptococcus infection, patients with Kawasaki disease, transplant recipients at risk for cytomegalovirus infection, patients with idiopathic thrombocytopenic purpura, and selected patients with chronic lymphocytic leukemia. Data are also favorable concerning the use of intravenous immunoglobulin in some other autoimmune disorders, but randomized trials are needed. Interesting areas for future study include the acquired immunodeficiency syndrome (AIDS), multiple myeloma, and lymphomas. Risks of intravenous immunoglobulin are minimal.

Conclusion: Intravenous immunoglobulin is safe and effective in treating several human diseases. Additional randomized trials are needed.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.